Condition

Neuroinflammation

ClinicalTrials.gov condition label

Clinical trials7

Recruiting0

Common interventions14

Lead sponsors shown5

Clinical trials

7 shown

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection FractionNCT07856043 · 2026-10-01

NOT_YET_RECRUITING

Effect of Tocopherol and Ascorbic Acid on Neuroinflammation Markers Associated With Neuropeptide Expression in the AgRP/NPY and POMC Pathways in Mexican Population With ObesityNCT07782411 · 2026-08-10

NOT_YET_RECRUITING

Effectiveness of Ashwagandha in Schizophrenia Patients on RisperidoneNCT07575516 · 2025-10-01

A Pilot Study of Adjunctive Structured Supportive Psychotherapy in SchizophreniaNCT07671040 · 2025-03-01

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentNCT06322342 · 2024-08-15

Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and PsoriasisNCT04423471 · 2021-02-01

The Effect of Celecoxib on Neuroinflammation in MDDNCT04814355 · 2018-08-01

Common interventions

[11C]PS13: [carbon-11]PS13; COX-1 PET radioligandDRUG1 Ascorbic acid (Vitamin C)DIETARY_SUPPLEMENT1 Ascorbic acid + tocopherol alphaCOMBINATION_PRODUCT1 AshwagandhaDRUG1 Celecoxib 400 mgDRUG1 PlaceboOTHER1 RisperidoneDRUG1 Risperidone 4mg/dayDRUG1 RVP-001DRUG1 Sacubitril-ValsartanDRUG1 Sociodemographic variablesDIAGNOSTIC_TEST1 Structured supportive psychotherapyBEHAVIORAL1 tocopherol alphaDIETARY_SUPPLEMENT1 Unstructured Supportive ConversationBEHAVIORAL1

Leading sponsors

Hasanuddin University2 Stony Brook University2 Autonomous University of Morelos1 Germans Trias i Pujol Hospital1 Reveal Pharmaceuticals Inc.1

Trial status mix

COMPLETED4

NOT_YET_RECRUITING2

WITHDRAWN1

Phase mix

NA2

PHASE22

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.